Analyst Ratings and Recommendations for Sanofi


Mar. 5 2018, Updated 10:31 a.m. ET

Wall Street analysts’ estimates

Sanofi (SNY) missed Wall Street analysts’ estimates for revenues and earnings per share (or EPS) in 4Q17. In 4Q17, Sanofi reported EPS of 1.06 euros on revenues of 8.7 billion euros, up from the EPS estimate of 0.98 euros on revenues of 8.5 billion euros.

The chart below shows the analyst recommendations for Sanofi stock over the last 12 months. Sanofi missed Wall Street analyst estimates for revenues and EPS in fiscal 2017. Sanofi reported EPS of 5.54 euros on revenues of 35.1 billion euros, up from the EPS estimate of 5.49 euros on revenues of 34.5 billion euros in fiscal 2017.

Article continues below advertisement

Analysts’ ratings

Sanofi’s (SNY) stock price has decreased ~5.6% over the last 12 months. SNY has decreased ~6.7% in 2018 year-to-date. Analyst estimates show that the stock has the potential to return ~19.6% over the next 12 months. 

Wall Street analysts’ recommendations show a 12-month target price of $48.00 per share compared to its price of $40.13 per share on February 23, 2018.

Analysts’ recommendations

On February 26, 2018, four analysts were tracking Sanofi ADR. Of these, one analyst recommended a “buy” while three analysts recommended a “hold.” None of the analysts recommended a “sell.” The consensus rating for Sanofi ADR is 2.5, which represents a moderate buy for long-term investors.

Also, 28 analysts are tracking Sanofi stock listed on Euronext Paris. Eleven of these analysts recommend a “buy,” 15 analysts recommend a “hold,” and two analysts recommend a “sell” for Sanofi stock. 

The changes in analysts’ estimates and recommendations are based on the company’s changing trends in stock price and performance. The consensus rating for Sanofi stands at ~2.5, which represents a moderate buy for value investors.

The First Trust BuyWrite Income ETF (FTHI) holds 9.4% of its total investments in healthcare companies. FTHI holds 0.2% in Sanofi ADR (SNY), 0.3% in Novo Nordisk ADR (NVO), 0.9% in Amgen (AMGN), and 1.4% in Gilead Sciences (GILD).


More From Market Realist